Stodaget beer Bodderker Joege	HUMAN RESOURCES HOUSE FILE BY (PROPOSED COMMITTEE ON HUMAN RESOURCES BILL BY CHAIRPERSON BODDICKER)
Passed House, Date	Passed Senate, Date
Vote: Ayes Nays	Vote: Ayes Nays
Approved	


## A BILL FOR

•

. .

٦	<b>N</b> m	Not	-	1-+	inc	~ +	~ +	hir	d-n	art	vn	avor	·	ove	rag	e fo	or d	off-	labe	l u	se
	An									arc	I P	ayor		0.00	249						
2			pre																		
3	BE	IT	ENA	CTE	DE	BY	THE	GE	ENER	AL	ASS	EMBI	LY (	OF	THE	ST	ATE	OF	IOWA	11	
4																					
5																					
6																					
7																					
8																					
9																					
10																					
11																					
12																					
13																					
14																					
15																					
16																					
17																					
18																					
19																					
20																					
21																					
22																					
23																					
- 23																т	T CD	21	0010	70	

TLSB 2180HC 78 mj/cf/24



Section 1. LEGISLATIVE FINDINGS. 1 The Iowa general 2 assembly finds and declares all of the following: 3 1. Third-party payors have denied payment for prescription 4 drugs that have been approved by the United States food and 5 drug administration, when the drugs are prescribed for uses 6 other than those stated on the marketing label approved by the 7 United States food and drug administration, while other 8 insurers with similar coverage terms do pay for off-label use. 9 Denial of payment for off-label uses interrupts necessary and 10 appropriate treatment for persons being treated for life-11 threatening illnesses by competent, responsible medical 12 professionals.

The United States food and drug administration and the 13 2. 14 United States department of health and human services 15 recognize the wide variety of effective uses of federally 16 approved drugs through off-label uses. Continuing medical 17 research has demonstrated effective, new uses of federally 18 approved drugs. Information on the appropriate off-label use 19 of federally approved drugs is obtained from compendia 20 published by the United States pharmacopeial convention or the 21 American society of hospital pharmacists. In addition, 22 scientific studies of off-label use of drugs published in 23 recognized peer-reviewed professional journals provide 24 information on appropriate off-label uses of drugs. The 25 federal Omnibus Budget Reconciliation Act of 1990 recognizes 26 these compendia and peer-reviewed literature as appropriate 27 sources for reimbursement.

3. The federal approval process for drugs is very expensive and time-consuming. Use of federally approved drugs for off-label uses provides efficacious drugs at a lower cost. To require that all appropriate uses of a drug undergo approval by the United States food and drug administration would substantially increase the cost of drugs, and delay or deny patients' ability to obtain medically effective treatment. To require approval for all new uses would add to

-1-

S.F. \_\_\_\_\_ H.F. \_\_\_

243

1 the already rising cost of prescription drugs.

4. Reimbursement for off-label uses of federally approved
3 drugs is necessary to conform to the way in which appropriate
4 medical treatment is provided, to make needed drugs available
5 to patients, and to contain health care costs.

6 Sec. 2. <u>NEW SECTION</u>. 514C.141 COVERAGE FOR OFF-LABEL USE 7 OF PRESCRIPTION DRUGS.

8 1. For purposes of this section, unless the context 9 otherwise requires:

10 a. "Medical literature" means published scientific studies 11 published in any peer-reviewed national professional journal 12 of medicine.

13 b. "Standard reference compendia" means any of the 14 following:

15 (1) The United States pharmacopoeia drug information.

16 (2) The American hospital formulary service drug
17 information.

18 (3) Drugdex.

19 2. Notwithstanding section 514C.6, a policy or contract 20 providing for third-party payment or prepayment of health care 21 or medical expenses shall not exclude coverage for a 22 prescription drug for a particular use on the basis that the 23 drug is prescribed for a use that is different from the use 24 for which that drug has been approved for marketing by the 25 United States food and drug administration, provided that all 26 the following conditions have been met:

a. The drug is approved for use by the United States foodand drug administration.

b. The drug is prescribed by a licensed health care
30 provider, participating under the policy or contract, for
31 appropriate medical treatment.

32 c. The drug has been recognized for the medical treatment 33 for which it was prescribed by one of the following:

34 (1) The American hospital formulary service drug35 information.

-2-

S.F. H.F.

(2) The United States pharmacopoeia dispensing
 2 information.

3 (3) One article from a major peer-reviewed medical journal 4 that presents data supporting the proposed off-label use or 5 uses as generally safe and effective unless there is clear and 6 convincing contradictory evidence presented in a major peer-7 reviewed medical journal.

8 3. A participating health care provider, if requested by a 9 third-party payor, shall submit to the third-party payor 10 documentation as identified in subsection 1, paragraph "c".

11 4. Coverage for a drug pursuant to this section also 12 includes medically necessary services associated with the 13 administration of the drug.

14 5. This section applies to the following classes of third-15 party payment provider contracts or policies delivered, issued 16 for delivery, continued, or renewed in this state on or after 17 January 1, 2000:

18 a. Individual or group accident and sickness insurance 19 providing coverage on an expense-incurred basis.

20 b. An individual or group hospital or medical service 21 contract issued pursuant to chapter 509, 514, or 514A.

22 c. An individual or group health maintenance organization23 contract regulated under chapter 514B.

d. An individual or group Medicare supplemental policy,
unless the coverage required by this section pursuant to such
a policy is preempted by federal law.

27 e. An organized delivery system licensed by the director28 of public health.

29 f. Any other entity engaged in the business of insurance, 30 risk transfer, or risk retention, which is subject to the 31 jurisdiction of the commissioner.

32 6. a. This section shall not be construed to alter 33 existing laws with regard to provisions limiting the coverage 34 of drugs that have not been approved by the United States food 35 and drug administration.

-3-

S.F. \_\_\_\_\_ H.F.

b. This section shall not be construed to require coverage
 for experimental drugs not otherwise approved for any use by
 the United States food and drug administration.

c. This section shall not reduce or limit coverage for
off-label use of drugs otherwise required by law or contract.
7. The commissioner shall create a panel of seven experts
7 to review off-label uses not included in any of the two
8 standard reference compendia or in the medical literature and
9 to give advice to the commissioner in such instances as to
10 whether a particular off-label use is medically appropriate.
11 The panel shall make such recommendations from time to time
12 and whenever a dispute about payment for an off-label use is
13 brought to the commissioner. The seven-member panel shall
14 include all of the following:

a. Three physicians licensed in this state as follows:
(1) One selected by the state medical oncology
17 association.

18 (2) One selected by the Iowa medical society.

19 (3) One selected by the American college of cardiology,20 Iowa chapter.

21 b. Two licensed pharmacists selected by the Iowa pharmacy 22 association.

23 c. Two laypersons selected by the commissioner.

24

## EXPLANATION

This bill creates new Code section 514C.14 which provides that a policy or contract providing for third-party payment or prepayment of health care or medical expenses shall not exclude coverage for a prescription drug for a particular use on the basis that the drug is prescribed for a use that is different from the use for which that drug has been approved for marketing by the United States food and drug administration, if the drug is approved for use by the United States food and drug administration; the drug is prescribed by a licensed health care provider, participating under the policy or contract, for appropriate medical treatment; and the

-4-

S.F. \_\_\_\_\_ H.F. \_\_\_\_

343

1 drug has been recognized for the medical treatment for which 2 it was prescribed by the American hospital formulary service 3 drug information, the United States pharmacopoeia dispensing 4 information, drugdex, or one article from a major peer-5 reviewed medical journal that presents data supporting the 6 proposed off-label use or uses as generally safe and effective 7 unless there is clear and convincing contradictory evidence 8 presented in a major peer-reviewed medical journal. The bill 9 provides that such coverage also includes medically necessary 10 services associated with the administration of the drug. 11 The bill applies to third-party payment provider contracts 12 or policies delivered, issued for delivery, continued, or 13 renewed in this state on or after January 1, 2000. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

-5-

LSB 2180HC 78 mj/cf/24

## MAR 1 8 1999

- 4

COMMERCE AND RECULATION

HOUSE FILE 726 BY COMMITTEE ON HUMAN RESOURCES

(SUCCESSOR TO HSB 243)

## A BILL FOR

•	2 3 4 5 6 7	of	pre	scri	ptio	on di	rugs.				-labe	el use	7
	8												¥
	9												H 72
	.0												N
	.1												
	.2												ลั
	.3												•••
	4												
	5			·									
	6												
	7									·			
	8												
	9												
	0									*			
	1												
2	2												

TLSB 2180HV 78 mj/cf/24 S.F. \_\_\_\_\_H.F. 720

Section 1. LEGISLATIVE FINDINGS. The Iowa general
 assembly finds and declares all of the following:
 I. Third-party payors have denied payment for prescription

4 drugs that have been approved by the United States food and 5 drug administration, when the drugs are prescribed for uses 6 other than those stated on the marketing label approved by the 7 United States food and drug administration, while other 8 insurers with similar coverage terms do pay for off-label use. 9 Denial of payment for off-label uses interrupts necessary and 10 appropriate treatment for persons being treated for life-11 threatening illnesses by competent, responsible medical 12 professionals.

13 2. The United States food and drug administration and the 14 United States department of health and human services 15 recognize the wide variety of effective uses of federally 16 approved drugs through off-label uses. Continuing medical 17 research has demonstrated effective, new uses of federally 18 approved drugs. Information on the appropriate off-label use 19 of federally approved drugs is obtained from compendia 20 published by the United States pharmacopeial convention or the 21 American society of hospital pharmacists. In addition, 22 scientific studies of off-label use of drugs published in 23 recognized peer-reviewed professional journals provide 24 information on appropriate off-label uses of drugs. The 25 federal Omnibus Budget Reconciliation Act of 1990 recognizes 26 these compendia and peer-reviewed literature as appropriate 27 sources for reimbursement.

3. The federal approval process for drugs is very expensive and time-consuming. Use of federally approved drugs for off-label uses provides efficacious drugs at a lower cost. To require that all appropriate uses of a drug undergo approval by the United States food and drug administration would substantially increase the cost of drugs, and delay or deny patients' ability to obtain medically effective treatment. To require approval for all new uses would add to

-1-

s.f. \_\_\_\_\_ H.f. 726

1 the already rising cost of prescription drugs.

4. Reimbursement for off-label uses of federally approved
3 drugs is necessary to conform to the way in which appropriate
4 medical treatment is provided, to make needed drugs available
5 to patients, and to contain health care costs.

6 Sec. 2. <u>NEW SECTION</u>. 514C.14 COVERAGE FOR OFF-LABEL USE 7 OF PRESCRIPTION DRUGS.

8 1. For purposes of this section, unless the context9 otherwise requires:

10 a. "Medical literature" means published scientific studies 11 published in any peer-reviewed national professional journal 12 of medicine.

13 b. "Standard reference compendia" means any of the 14 following:

15

(1) The United States pharmacopoeia drug information.

16 (2) The American hospital formulary service drug 17 information.

18 (3) Drugdex.

19 2. Notwithstanding section 514C.6, a policy or contract 20 providing for third-party payment or prepayment of health care 21 or medical expenses shall not exclude coverage for a 22 prescription drug for a particular use on the basis that the 23 drug is prescribed for a use that is different from the use 24 for which that drug has been approved for marketing by the 25 United States food and drug administration, provided that all 26 the following conditions have been met:

a. The drug is approved for use by the United States foodand drug administration.

29 b. The drug is prescribed by a licensed health care 30 provider, participating under the policy or contract, for 31 appropriate medical treatment.

32 c. The drug has been recognized for the medical treatment 33 for which it was prescribed by one of the following:

34 (1) The American hospital formulary service drug35 information.



1

s.f. H.f. 726

(2) The United States pharmacopoeia dispensing
 2 information.

3 (3) One article from a major peer-reviewed medical journal 4 that presents data supporting the proposed off-label use or 5 uses as generally safe and effective unless there is clear and 6 convincing contradictory evidence presented in a major peer-7 reviewed medical journal.

3. A participating health care provider, if requested by a
9 third-party payor, shall submit to the third-party payor
10 documentation as identified in subsection 2, paragraph "c".
11 4. Coverage for a drug pursuant to this section also
12 includes medically necessary services associated with the
13 administration of the drug.

14 5. This section applies to the following classes of third-15 party payment provider contracts or policies delivered, issued 16 for delivery, continued, or renewed in this state on or after 17 January 1, 2000:

18 a. Individual or group accident and sickness insurance19 providing coverage on an expense-incurred basis.

b. An individual or group hospital or medical service
contract issued pursuant to chapter 509, 514, or 514A.
c. An individual or group health maintenance organization

23 contract regulated under chapter 514B.

d. An individual or group Medicare supplemental policy,
unless the coverage required by this section pursuant to such
a policy is preempted by federal law.

27 e. An organized delivery system licensed by the director28 of public health.

29 f. Any other entity engaged in the business of insurance, 30 risk transfer, or risk retention, which is subject to the 31 jurisdiction of the commissioner.

32 6. a. This section shall not be construed to alter 33 existing laws with regard to provisions limiting the coverage 34 of drugs that have not been approved by the United States food 35 and drug administration.

-3-

S.F. \_\_\_\_\_ H.F. 726

b. This section shall not be construed to require coverage
 for experimental drugs not otherwise approved for any use by
 the United States food and drug administration.

c. This section shall not reduce or limit coverage for
off-label use of drugs otherwise required by law or contract.
7. The commissioner shall create a panel of seven experts
7 to review off-label uses not included in any of the three
8 standard reference compendia or in the medical literature and
9 to give advice to the commissioner in such instances as to
10 whether a particular off-label use is medically appropriate.
11 The panel shall make such recommendations from time to time
12 and whenever a dispute about payment for an off-label use is
13 brought to the commissioner. The seven-member panel shall
14 include all of the following:

a. Three physicians licensed in this state as follows:
(1) One selected by the state medical oncology
17 association.

18 (2) One selected by the Iowa medical society.

19 (3) One selected by the American college of cardiology,20 Iowa chapter.

21 b. Three licensed pharmacists selected by the Iowa 22 pharmacy association.

23 c. One layperson selected by the commissioner.

24

EXPLANATION

This bill creates new Code section 514C.14 which provides that a policy or contract providing for third-party payment or prepayment of health care or medical expenses shall not exclude coverage for a prescription drug for a particular use on the basis that the drug is prescribed for a use that is different from the use for which that drug has been approved for marketing by the United States food and drug administration, if the drug is approved for use by the United States food and drug administration; the drug is prescribed by a licensed health care provider, participating under the policy or contract, for appropriate medical treatment; and the

-4-

S.F. H.F. 726

1 drug has been recognized for the medical treatment for which 2 it was prescribed by the American hospital formulary service 3 drug information, the United States pharmacopoeia dispensing 4 information, drugdex, or one article from a major peer-5 reviewed medical journal that presents data supporting the 6 proposed off-label use or uses as generally safe and effective 7 unless there is clear and convincing contradictory evidence 8 presented in a major peer-reviewed medical journal. The bill 9 provides that such coverage also includes medically necessary 10 services associated with the administration of the drug. 11 The bill applies to third-party payment provider contracts 12 or policies delivered, issued for delivery, continued, or 13 renewed in this state on or after January 1, 2000. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

> LSB 2180HV 78 mj/cf/24.1